Valerio Therapeutics ALONX.PA Stock
Valerio Therapeutics Price Chart
Valerio Therapeutics ALONX.PA Financial and Trading Overview
| Valerio Therapeutics stock price | 0.27 EUR |
| Previous Close | 0.27 EUR |
| Open | 0.28 EUR |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.27 - 0.28 EUR |
| 52 Week Range | 0.13 - 0.75 EUR |
| Volume | 9.12K EUR |
| Avg. Volume | 110.93K EUR |
| Market Cap | 30.17M EUR |
| Beta (5Y Monthly) | 1.858027 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.4 EUR |
ALONX.PA Valuation Measures
| Enterprise Value | 25.72M EUR |
| Trailing P/E | N/A |
| Forward P/E | 0.46101698 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 20.910072 |
| Price/Book (mrq) | 1.3532338 |
| Enterprise Value/Revenue | 17.825 |
| Enterprise Value/EBITDA | -1.51 |
Trading Information
Valerio Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.858027 |
| 52-Week Change | -20.55% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.75 EUR |
| 52 Week Low | 0.13 EUR |
| 50-Day Moving Average | 0.3 EUR |
| 200-Day Moving Average | 0.29 EUR |
ALONX.PA Share Statistics
| Avg. Volume (3 month) | 110.93K EUR |
| Avg. Daily Volume (10-Days) | 40.12K EUR |
| Shares Outstanding | 110.93M |
| Float | N/A |
| Short Ratio | N/A |
| % Held by Insiders | 13.25% |
| % Held by Institutions | 12.72% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1185.93% |
| Gross Margin | 64.37% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -22.24% |
| Return on Equity (ttm) | -70.86% |
Income Statement
| Revenue (ttm) | 1.44M EUR |
| Revenue Per Share (ttm) | 0.01 EUR |
| Quarterly Revenue Growth (yoy) | -58.50% |
| Gross Profit (ttm) | N/A |
| EBITDA | -17037000 EUR |
| Net Income Avi to Common (ttm) | -19562000 EUR |
| Diluted EPS (ttm) | -0.18 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 14.59M EUR |
| Total Cash Per Share (mrq) | 0.13 EUR |
| Total Debt (mrq) | 10.13M EUR |
| Total Debt/Equity (mrq) | 45.51 EUR |
| Current Ratio (mrq) | 2.879 |
| Book Value Per Share (mrq) | 0.201 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -9443000 EUR |
| Levered Free Cash Flow (ttm) | -2918750 EUR |
Profile of Valerio Therapeutics
| Country | France |
| State | N/A |
| City | Paris |
| Address | 49, boulevard du GEnEral Martial Valin |
| ZIP | 75015 |
| Phone | 33 1 45 58 76 00 |
| Website | https://www.onxeo.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 25 |
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was incorporated in 1997 and is headquartered in Paris, France.
Q&A For Valerio Therapeutics Stock
What is a current ALONX.PA stock price?
Valerio Therapeutics ALONX.PA stock price today per share is 0.27 EUR.
How to purchase Valerio Therapeutics stock?
You can buy ALONX.PA shares on the Paris exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Valerio Therapeutics?
The stock symbol or ticker of Valerio Therapeutics is ALONX.PA.
Which industry does the Valerio Therapeutics company belong to?
The Valerio Therapeutics industry is Biotechnology.
How many shares does Valerio Therapeutics have in circulation?
The max supply of Valerio Therapeutics shares is 110.93M.
What is Valerio Therapeutics Price to Earnings Ratio (PE Ratio)?
Valerio Therapeutics PE Ratio is 0.00000000 now.
What was Valerio Therapeutics earnings per share over the trailing 12 months (TTM)?
Valerio Therapeutics EPS is 0 EUR over the trailing 12 months.
Which sector does the Valerio Therapeutics company belong to?
The Valerio Therapeutics sector is Healthcare.